Gynecologic Oncology Group

How to interpret these research links

Connected source records

The exact organization name Gynecologic Oncology Group appears in 10 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials10

Recruiting shown0

Roles2

SourceClinicalTrials.gov

Clinical trials

10 shown

Cost of Cancer Risk Management in Women at Elevated Genetic Risk for Ovarian Cancer Who Participated on GOG-0199NCT01445275 · lead sponsor · 2011-01-01

WITHDRAWN

Incidence of Cancer in Women at Increased Genetic Risk of Ovarian CancerNCT01139957 · lead sponsor · 2010-06-07

COMPLETED

Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial CancerNCT00807768 · lead sponsor · 2009-03-23

UNKNOWN

Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00899145 · lead sponsor · 2008-05-01

WITHDRAWN

Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation CarriersNCT00897455 · lead sponsor · 2008-04-01

UNKNOWN

Zoledronate or Observation in Maintaining Bone Mineral Density in Patients Who Are Undergoing Surgery to Remove Both OvariesNCT00305695 · lead sponsor · 2005-11-28

COMPLETED

Collecting Tumor Samples From Patients With Gynecological TumorsNCT00897442 · lead sponsor · 1992-06-01

COMPLETED

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)NCT04634877 · collaborator · 2021-01-10

ACTIVE_NOT_RECRUITING

Clinical Effectiveness of First Trimester Pre-eclampsia Screening Program.NCT04021680 · collaborator · 2019-06-10

UNKNOWN

Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · collaborator · 2018-12-18

COMPLETED

Drugs studied in this sponsor's trials

6 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Gynecologic Oncology Group as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

carboplatin3

paclitaxel3

docetaxel2

cisplatin1

olaparib1

zoledronic acid1

carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials paclitaxel RxCUI 56946 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 3 trials docetaxel RxCUI 72962 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 2 trials cisplatin RxCUI 2555 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial zoledronic acid RxCUI 77655 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor7

collaborator3

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.